CA AB2300

Prohibits manufacturing, selling, or distributing intravenous solution containers made with intentionally added DEHP in California starting January 1, 2030, with an extended deadline of January 1, 2032 for manufacturers with pending FDA approval or inadequate equipment if customers are notified by July 1, 2025.

Prohibits manufacturing, selling, or distributing intravenous tubing made with intentionally added DEHP in California starting January 1, 2035.

Prohibits intravenous solution containers and tubing from containing unintentionally added DEHP at concentrations of 0.1% weight per weight or above.

Prohibits manufacturers from replacing DEHP with other ortho-phthalates in revised or new products.

Exempts human blood collection and storage bags, and apheresis and cell therapy blood kits and bags from these requirements.